CG Oncology (CGON) Total Non-Current Liabilities (2023 - 2026)

CG Oncology's Total Non-Current Liabilities history runs 4 years deep, the most recent figure standing at $42.0 million for Q1 2026.

• Quarterly Total Non-Current Liabilities changed N/A year-over-year to $42.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $42.0 million (changed N/A YoY) and the FY2025 annual result came in at $37.2 million, up 73.9% from the prior year.
• Total Non-Current Liabilities was $42.0 million for Q1 2026 at CG Oncology, up from $37.2 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $42.0 million in Q1 2026 and bottomed at $14.1 million in Q4 2023.
• A 4-year average of $30.7 million and a median of $37.2 million in 2025 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2024 — Total Non-Current Liabilities soared 51.42% — and 2025, when it jumped 73.9%.
• CG Oncology's Total Non-Current Liabilities stood at $14.1 million in 2023, then soared by 51.42% to $21.4 million in 2024, then soared by 73.9% to $37.2 million in 2025, then rose by 12.84% to $42.0 million in 2026.
• Business Quant data shows CGON's Total Non-Current Liabilities at $42.0 million in Q1 2026, $37.2 million in Q4 2025, and $38.5 million in Q3 2025.